Opinion/decision on a Paediatric investigation plan (PIP): Rezzayo, rezafungin acetate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0343/2024

EMA/PE/0000236239

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, PIP number: P/0028/2023

EMA/PE/0000232757

EMA/PE/0000182928

EMEA-003489-PIP01-23

EMEA-003489-PIP02-23

EMEA-003435-PIP02-23

EMA/PE/0000232774

Human medicines European public assessment report (EPAR): Aquipta, atogepant, Date of authorisation: 11/08/2023, Revision: 6, Status: Authorised